A pharmaceutical preparation for preventing or treating pruritic symptoms which contains as an effective ingredient a
prostaglandin derivative represented by formula [1]wherein X1 and X2 which are different from each other represent a
hydrogen atom, a
halogen atom or a hydroxyl group; Y is an
ethylene group, a
vinylene group or an ethynylene group; Z is the formula (CH2)kA(CH2)hB(CH2)q, (CH2)kA(CH2)rA′(CH2)t (CH2)kB(CH2)hB′(CH2)q or (CH2)k-1B′(CH2)q-1A′wherein k is an integer of 1 to 4, h is an integer of 0 to 4, q is an integer 1 to 4, r is an integer of 0 to 4, and t is an integer of 0 to 2; A and A′ which may be the same or different represent an
ethylene group, a
vinylene group or an ethynylene group; B and B′ which may be the same or different represent an
oxygen atom or a group represented by the formula S(O)u wherein u is an integer of 0 to 2; W1 is a hydroxyl group, a C1-10 alkyloxy group, a C3-10 cycloalkyloxy group, an aryloxy group or an arylalkyloxy group; W2 is a C1-10
alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group, a C3-10 cycloalkyl group, a C1-5
alkyl group substituted by C3-10 cycloalkyl group(s), or a group represented by the formula wherein W4 is a C1-10
alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group or a C1-5 alkyl group substituted by C3-10 cycloalkyl group(s); v is an integer of 0 to 4; W3 is a
hydrogen atom or a
methyl group, or W3 when taken together with W2 and the adjacent
carbon atom forms a C3-10 cycloalkyl group; m is 0 or 1, a pharmaceutically acceptable salt thereof or a
hydrate thereof.